American Express Co. stock outperforms competitors
Is It Too Late to Buy American Express Stock?
Shares of American Express (NYSE: AXP) have skyrocketed to an all-time high with a 44% return this year, outperforming the 20% gain in the S&P 500 index. The financial services giant has benefited from resilient macroeconomic conditions, driving solid growth and stronger earnings. Shareholders have had plenty to cheer about lately.
American Express (AXP) closed the latest trading day at $271.20, indicating a +0.05% change from the previous session's end. This move lagged the S&P 500's daily gain of 0.42%. Meanwhile, the Dow ...
Analyst Donald Fandetti from Wells Fargo maintained a Buy rating on American Express (AXP – Research Report) and increased the price ...
The Delta SkyMiles American Express Card lineup recently released fresh, limited-time offers for new personal and business ...
If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider American Express ...
Credit cards are a handy financial tool for a number of reasons, but I’ve always been interested in them for the rewards they ...
4d
Few cards are as well-known as Centurion cards. But does the Business Centurion deserve the hype? Read our full Amex Business ...
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from ...
Terms apply to American Express benefits and offers. Visit americanexpress.com to learn more. The new application experience is currently available for individuals applying for a U.S. Personal ...
This version of the Amex Platinum Card is exclusively for Schwab clients and has extra benefits. Check out how it works in ...
Our opinions are our own. American Express made its name with cards that were as much status symbols as payment methods. In the 21st century, the issuer offers a complete line of cards with ...
NVIDIA, American Express, Wells Fargo, Elite Pharmaceuticals and PrimeEnergy are included in this Analyst Blog.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback